Lineage Cell Therapeutics (LCTX) Other Working Capital Changes (2010 - 2026)
Lineage Cell Therapeutics (LCTX) posted quarterly Other Working Capital Changes of -$3.0 million for Q2 2023, up 28.53% year-over-year from -$2.3 million in Q2 2022, and down 39.51% quarter-over-quarter from -$2.1 million in Q1 2023.
Lineage Cell Therapeutics (LCTX) Other Working Capital Changes (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Other Working Capital Changes history runs 12 years deep, the most recent figure standing at -$3.0 million for Q2 2023.
- In Q2 2023, Other Working Capital Changes rose 28.53% year-over-year to -$3.0 million; the TTM figure through Jun 2023 stood at -$9.4 million (down 4.22% YoY), while the FY2022 annual figure was -$13.4 million, down 3614.21% from the prior year.
- Other Working Capital Changes for Q2 2023 stood at -$3.0 million, down from -$2.1 million in the prior quarter.
- The five-year high for Other Working Capital Changes was $6.5 million in Q4 2023, with the low at -$12.8 million in Q4 2022.
- The 5-year median for Other Working Capital Changes is -$598000.0 (2024), against an average of -$850941.2.
- The sharpest annual moves came in 2021 and 2022: Other Working Capital Changes jumped 537.93% in 2021, then sank 5556.98% in 2022.
- Lineage Cell Therapeutics' Other Working Capital Changes stood at -$378000.0 in 2019, then soared by 69.31% to -$116000.0 in 2020, then sank by 248.28% to -$404000.0 in 2021, then plunged by 336.39% to -$1.8 million in 2022, then tumbled by 67.84% to -$3.0 million in 2023.
- Business Quant data shows LCTX's Other Working Capital Changes at -$3.0 million in Q2 2023, -$2.1 million in Q1 2023, and -$1.8 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -698,000.00 |
| Jun 30, 2026 | -698,000.00 |
| Jun 30, 2026 | -698,000.00 |
| Mar 31, 2026 | -995,000.00 |
| Mar 31, 2026 | -995,000.00 |
| Mar 31, 2026 | -995,000.00 |
| Dec 31, 2025 | 1.03 Mn |
| Dec 31, 2025 | 1.03 Mn |
| Dec 31, 2025 | 1.03 Mn |
| Sep 30, 2025 | 194,000.00 |
| Sep 30, 2025 | 194,000.00 |
| Sep 30, 2025 | 194,000.00 |
| Jun 30, 2025 | 8,000.00 |
| Jun 30, 2025 | 8,000.00 |
| Jun 30, 2025 | 8,000.00 |
| Mar 31, 2025 | -1.28 Mn |
| Mar 31, 2025 | -1.28 Mn |
| Mar 31, 2025 | -1.28 Mn |
| Dec 31, 2024 | 4.71 Mn |
| Dec 31, 2024 | 4.71 Mn |